ARHGEF17 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population in which the ARHGEF17 gene has been disrupted to create a loss-of-function model. The polyclonal pool preserves population-level genetic diversity while eliminating functional ARHGEF17 expression, avoiding clonal selection artifacts. This format supports robust, reproducible assays and is suitable for a broad range of functional studies in lung adenocarcinoma research.
The A-549 cell line is a well-established human epithelial lung carcinoma model originating from a 58-year-old male with lung adenocarcinoma. These cells exhibit features of alveolar type II pneumocytes and are a standard platform for studying lung adenocarcinoma biology, including proliferation, migration, and angiogenesis. Their expression of VEGFR and integrins makes them particularly apt for interrogating growth factor- and adhesion-driven signaling.
ARHGEF17 encodes a RhoA-specific guanine nucleotide exchange factor that catalyzes the conversion of RhoA-GDP to RhoA-GTP. Active RhoA then engages ROCK1/2, which phosphorylates LIMK, leading to cofilin inactivation and subsequent stabilization of filamentous actin, while also promoting MLC phosphorylation and actomyosin contractility. This pathway is initiated by VEGF, EGF, and integrin clustering and converges on focal adhesion assembly and SRF/MRTF-mediated transcription. ARHGEF17 interacts directly with RhoA, integrin cytoplasmic domains, and focal adhesion kinase (FAK), positioning it as a critical node linking growth factor and adhesion signaling to cellular mechanics and gene expression.
Disruption of ARHGEF17 in A-549 cells attenuates RhoA signaling, reducing ROCK activity, MLC phosphorylation, and focal adhesion assembly. The consequent loss of migratory and angiogenic capacity mirrors the role of ARHGEF17 in driving metastatic and pro-angiogenic phenotypes in lung adenocarcinoma. This polyclonal knockout model therefore enables physiologically relevant dissection of RhoGEF-dependent malignant traits.
This knockout cell tool is designed for diverse experimental approaches, including western blotting for RhoA/ROCK/phospho-MLC, RhoA activation assays, transwell migration and invasion assays, phalloidin staining for F-actin, and tube formation assays. It serves as a platform for validating ARHGEF17 as a target in anti-angiogenic therapy and for mechanistic studies of Rho GTPase signaling within a lung cancer milieu. Researchers may also combine it with pharmacological inhibitors or cDNA rescue experiments to explore pathway dynamics. For additional technical details, please contact Ascent Research.
